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Background: Cellular metabolism is highly dynamic and continuously adjusts to the physiological program of the
cell. The regulation of metabolism appears at all biological levels: (post-) transcriptional, (post-) translational, and
allosteric. This regulatory information is expressed in the metabolome, but in a complex manner. To decode such
complex information, new methods are needed in order to facilitate dynamic metabolic characterization at high
resolution.
Results: Here, we describe pulsed stable isotope-resolved metabolomics (pSIRM) as a tool for the dynamic
metabolic characterization of cellular metabolism. We have adapted gas chromatography-coupled mass
spectrometric methods for metabolomic profiling and stable isotope-resolved metabolomics. In addition, we have
improved robustness and reproducibility and implemented a strategy for the absolute quantification of metabolites.
Conclusions: By way of examples, we have applied this methodology to characterize central carbon metabolism of
a panel of cancer cell lines and to determine the mode of metabolic inhibition of glycolytic inhibitors in times
ranging from minutes to hours. Using pSIRM, we observed that 2-deoxyglucose is a metabolic inhibitor, but does
not directly act on the glycolytic cascade.
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Central metabolism is highly flexible and continuously
adjusts to the physiological program of the cell, organ,
and organism. In a healthy state, cellular metabolism is
tightly regulated to guarantee physiological function and
the efficient usage of available resources. However, the
underlying mechanisms leading to metabolic dysfunction
are often poorly understood. To gain deeper insights
into the dynamics of metabolism, techniques enabling a
quantitative and time-resolved analysis of the metabolome
are needed to allow a detailed real-time view of carbon* Correspondence: stefan.kempa@mdc-berlin.de
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unless otherwise stated.routing through central carbon metabolism (CCM):
glycolysis, pentose phosphate pathway (PPP), tricarboxylic
acid cycle (TCA) cycle, and amino acid metabolism.
Metabolic flux is an expression of the activity of a
network of enzymatic reactions. This network is influ-
enced by several factors: the expression levels of the
catalytic enzymes and the relative concentrations of
substrates and products. In addition, allosteric regula-
tion and post-translational modifications, including
phosphorylation, ubiquitylation and, most recently rec-
ognized, acetylation, control metabolic activity. Meta-
bolic flux cannot be inferred from transcript or protein
levels of constituent enzymes, but rather requires dir-
ect measurement. Several techniques for metabolic flux
analysis (MFA) have been established previously. Flux
balance analysis (FBA) and stoichiometric MFA rely onLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cretion of the cellular system over time [1,2]. Integra-
tion of further parameters, such as cell growth and
biomass production, provides an overall quantification
of metabolic performance.
However, such methods particularly fail in the case of
parallel or circular metabolic pathways [3]. In addition,
unlike bacteria, mammalian cells contain different com-
partments and are not optimized to reach maximum
biosynthesis and growth rate, making calculations and
modeling more complex and error-prone [4].
To solve these difficulties and improve the quality of
measurements, isotopes were introduced into the moni-
tored systems. In the early days of biochemistry, radio-
active isotopes were used to assess the operation of the
most important metabolic pathways: glycolysis [5], the
TCA cycle [6], and the Calvin-Benson cycle [7]. As early
as 1977, radioisotopes were applied to trace carbon flow
throughout rat metabolism in vivo [8]. Recently, stable
isotopes have been applied to humans [9]. Nowadays,
the use of stable isotopes (e.g., carbon-13 or nitrogen-15)
in combination with mass spectrometry or nuclear mag-
netic resonance allows a detailed analysis of metabolism
[10]. Typically, a mixture of stable isotope-labeled sub-
strates is fed to cells, producing complex isotope distri-
bution patterns of metabolic intermediates [11,12]. The
analysis of these patterns with mathematical models
that consider the network structure and carbon transi-
tions increases knowledge about metabolic activity and
carbon routing within the cellular system [13]. Such
studies have already given new insights into the regula-
tion of the central metabolism by well-characterized
oncogenes [14]. However, with increased sensitivity of
recently developed analytical systems, it is now possible
to detect 13C enrichment in free metabolites, instead of
the more abundant protein-bound amino acids, thereby
enabling a switch from stationary to instationary meta-
bolic flux analysis [15].
Herein, we report the development of a strategy that
allows for the direct measurement of dynamic metabolic
activity through central carbon pathways using stable
isotopes and mass spectrometry. The workflow presented
is designed to achieve a comprehensive measurement
of CCM with broad coverage of intermediates. Stable
isotope-labeled substrates are applied to cells, and time-
resolved isotope enrichment and quantification of
downstream metabolites can be performed within a
single measurement—we termed this workflow pulsed
stable isotope-resolved metabolomics (pSIRM).
The concept is similar to the dynamic metabolic
flux analysis introduced for microorganisms by Nöh
and Wiechert [16]. Due to the instationary isotope
incorporation, metabolites that are tightly connected
to the introduced substrates will display a higher isotopeincorporation than the metabolites that are more
distant [17].
Assessing the dynamics of CCM in minute timeframes
enabled the comparison of carbon routing in several com-
monly used cancer cell lines and exploration of the mode of
action of the glycolytic inhibitors 3-bromopyruvate (BrPyr)
or 2-deoxyglucose (2DG). Surprisingly, we observed that
2DG does not directly block glycolysis but rather interferes
with phosphate and thus ATP metabolism. In summary, we
show that the pSIRM approach facilitates the identification
of metabolic dysregulation directly, without the need
to separately calculate metabolic fluxes [18].
Methods
Chemicals
Stable isotope-labeled substrates were purchased at the
following company: u-13C-glucose and 13C1-glucose are
from Campro Scientific (Berlin, Germany). Extraction
chemicals methanol and chloroform were products of
Merck (Whitehouse Station, NJ, USA). All other che-
micals were bought in highest quality at Sigma-Aldrich
(St. Louis, MO, USA) unless otherwise noted.
Cell culture
Dr. Ulrike Ziebold (MDC Berlin-Buch, T98G, HeLa,
HCT-116) and Dr. Markus Landthaler (MDC Berlin-Buch,
HEK293) kindly provided the cell lines. The cell lines
were cultivated in glucose-free Dulbecco's modified
Eagle's medium (DMEM; Invitrogen, Renfrew, Scotland)
supplemented with 2.5 g/l glucose, 10% fetal bovine serum
(Invitrogen), and 1% penicillin/streptomycin (Invitrogen)
and cultivated at 37°C in 5% CO2. The cells were pas-
saged with appropriate split ratios every 3 days. Viable
cell numbers were determined by trypan blue staining
(0.04%, Invitrogen) and automated counting (BioRad,
Hercules, CA, USA).
pSIRM experiment
Cell culture/cell seeding
The number of cells for plating was determined to avoid
contact inhibitory effects during the experiment for each
cell line and nutrient condition separately. After seed-
ing, the cells were cultured for 2 or 3 days. During that
time, cell culture media was replaced 24 and 4 h prior
to harvest.
Cell labeling/harvest
The adherent growth behavior of the used cell lines
allowed the labeling with 13C substrates directly on the
cell culture dish. Therefore, the cell culture medium was
replaced with pre-warmed full label medium containing
all carbon sources and supplements like standard cell
culture for a defined time range. One carbon source was
substituted with its carbon-13 variant according to the
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flushed with label buffer (140 mM NaCl, 5 mM HEPES
(Roth, Karlsruhe, Germany) with pH 7.4, major carbon
sources according full label media) to remove extracellular
metabolites. Immediately, the cells were quenched with
5 ml −20°C cold 50% methanol (containing cinnamic
acid (2 μg/ml)). The cells were scratched from the culture
dish in the solvent, transferred into a 15-ml falcon, and
stored on ice or at −25°C until proceeding with metab-
olite extraction. In the pSIRM experiments with an ap-
plication of 13C substrates for less than 5 min, the cells
were incubated in label buffer directly.
Metabolite extraction
Methanol-chloroform-water extraction provides an effect-
ive extraction and subsequent separation of lipid and polar
intermediates. One milliliter chloroform was added to
5 ml of methanolic cell extracts, shaken for 30 min at 4°C,
and centrifuged at maximum speed for 15 min for phase
separation. Both phases were collected separately and
dried under vacuum. The extracts were stored at −25°C.
GC-MS analysis
Derivatization was carried out as described with modi-
fications [19]. The dried cell extracts were dissolved in
20 μl of methoxyamine hydrochloride solution (Sigma,
40 mg/ml in pyridine (Roth)) and incubated for 90 min
at 30°C with constant shaking followed by the addition
of 80 μl of N-methyl-N-[trimethylsilyl]trifluoroacetamide
(MSTFA; Machery-Nagel, Dueren, Germany) and incu-
bation at 37°C for 45 min. The extracts were centrifuged
for 10 min at 10,000 × g, and aliquots of 30 μl were
transferred into glass vials (Th. Geyer, Berlin, Germany)
for gas chromatography-mass spectrometry (GC-MS)
measurement.
Retention index standard
Nine alkanes (n-decane, n-dodecane, n-pentadecane,
n-octadecane, n-nonadecane, n-docosane, n-octacosane,
n-dotriacontane, and n-hexatriacontane) were dissolved in
hexane, combined at a final concentration of 2 mg/ml and
stored at 4°C. Retention index standard was added to
the solvent (MSTFA) at a final concentration of 2% (v/v)
during derivatization.
Quantification standard
The quantification mixture was composed of 63 com-
pounds (stock concentration 1 mg/ml, 20% MeOH). A
dilution series from 1:1, 1:2, 1:5, 1:10, 1:20, 1:50, 1:100,
and 1:200 was prepared, portioned, dried under vac-
uum, and stored at −20°C. One set of quantification
standard was treated in parallel with cell extracts dur-
ing derivatization and measured in technical replicates
within an experiment.GC-MS measurement
Metabolite analysis was performed on a gas chroma-
tography coupled to time of flight mass spectrometer
(Pegasus III- TOF-MS-System, LECO Corp., St. Joseph, MI,
USA), complemented with an auto-sampler (MultiPurpose
Sampler 2 XL, Gerstel, Mülheim an der Ruhr, Germany).
The samples and quantification standards were injected
in split mode (split 1:5, injection volume 1 μl) in a
temperature-controlled injector (CAS4, Gerstel) with a
baffled glass liner (Gerstel). The following temperature
program was applied during sample injection: initial
temperature of 80°C for 30 s followed by a ramp with
12°C/min to 120°C and a second ramp with 7°C/min to
300°C and final hold for 2 min. Gas chromatographic separ-
ation was performed on an Agilent 6890 N (Agilent, Santa
Clara, CA, USA), equipped with a VF-5 ms column of
30-m length, 250-μm inner diameter, and 0.25-μm film
thickness (Varian, Palo Alto, CA, USA). Helium was used
as carrier gas with a flow rate of 1.2 ml/min. Gas chroma-
tography was performed with the following temperature
gradient: 2-min heating at 70°C, first temperature gradient
with 5°C/min up to 120°C and hold for 30 s; subsequently,
a second temperature increase of 7°C/min up to 350°C
with a hold time of 2 min. The spectra were recorded in a
mass range of 60 to 600 U with 20 spectra/s at a detector
voltage of 1750 V.
Data analysis
The vendor software ChromaTOF Version 4.42 (LECO)
was used for metabolite evaluation with the following
parameters: baseline offset of 1, peak width of 4 s, signal/
noise of 20, and peak smoothing of 11 data points. Re-
tention indices were calculated based on retention
index standards. The Golm Metabolome Database (GMD)
provided mass spectra and retention information for
peak identification [20]. The quantification routine of
ChromaTOF was used for external calibration based
on the measured quantification standards. Exported .txt
files included the following: name, quantification mass
retention index, first dimension retention time, second
dimension retention time, area, concentration, match,
reverse, quantitative signal/noise, type, concentration
units, and the peak true spectrum in absolute values.
For further data analysis, the tool MetMax was developed
in cooperation with the MPIMP in Potsdam-Golm
(http://gmd.mpimp-golm.mpg.de/apps/metmax) [21].
MetMax provided the extraction of peak areas and
quantities (retention analysis mode) and intensities of
pre-defined mass ranges (isotope concentrator mode)
from the exported .txt files. The in-house-developed
pSIRM-wizard enabled the determination of 13C-label
incorporation based on the exported data following the de-
scriptions and equations stated in the paper. The R package
is available on request.
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Reproducibility
T98G cells were seeded (6.5 × 105 cells/10-cm cell culture
dish) in 10 ml DMEM (2.5 g/l glucose, 4 mM glutamine,
10% FBS, and 1% pen/strep) and cultivated for 3 days. Media
changes were performed 24 and 4 h prior the harvest
to avoid nutrient deprivation.
Stable isotope labeling with 13C glucose was applied at
three independent dishes for 3 min. Cell harvest and ex-
traction was carried out as described above. The extracts
of all dishes were pooled, portioned, and measured six
times to evaluate technical reproducibility. The bio-
logical variance was determined by the measurement of
five individually handled dishes of T98G cells measured
in four technical replicates. In addition, two plates of
T98G cells were harvested with 12C glucose for the ac-
quisition of reference spectra.
Quantification addition
Seven dishes of T98G cells were harvested as described
above. The cells were extracted a second time with 20%
(v/v) MeOH containing an internal standard (cinnamic
acid, 2 μg/ml), and pooled. Quantification mixtures and
quantification mixtures with spiked in cell extracts as well
as cell extracts were measured, and recovery was calculated
from these data.
Verification of calculation strategy by the measurement of
known ratios of 13C1-Glc and
12C-Glc
One milligram per milliliter stock solutions of glucose
and 13C1-glucose (Campro Scientific) were prepared in
20% MeOH and mixed in known ratios of 0%, 2%, 5%, 10%,
25%, 50%, 75%, 90%, 95%, 98%, and 100% of 13C1-glucose;
three independent batches were prepared. Twenty
microliters were dried under vacuum, derivatized, and
measured as described above. Measurement and data
extraction were performed as described and uncor-
rected, targeted, and position-independent strategies
applied.
Metabolic profiling of cell lines
T98G, HEK293, HeLa, and HCT-116 were grown for ana-
lysis of the metabolic profile under identical nutrient condi-
tions (DMEM, 10% FBS, 2.5 g/l glucose, 4 mM glutamine).
Seeding densities were evaluated in advance to avoid con-
tact inhibition. Labeling with 13C-glucose and cell harvest
were performed as described. Three dishes for each cell line
were pooled, processed as described above, and measured
in technical replicates.
Glycolytic inhibition
T98G cells were seeded and harvested as described for
the reproducibility experiment. Inhibitors were added in
the following concentrations separately for 12 min: 2 mMBrPyr and 2, 4, and 10 mM 2DG. On a separate dish,
2 mM mannitol was applied as osmotic control. Subse-
quently, media were replaced with 5ml pre-warmed
labeling buffer containing 2.5 g/l u-13C-glucose, 2 mM
glutamine, and inhibitors for 3 min. Cell harvest, ex-
traction, and metabolite measurement were performed
as described above.
Results
Coverage of intermediates of CCM
CCM comprises a large number of small molecules dif-
fering in their chemical properties, making detection
and quantification of all intermediates using a single
technique challenging. We have further developed GC-
MS-based metabolomics to measure the intermediates
of CCM with broad coverage, in absolute quantities, and
to extract isotope information from the fragment spectra.
This improved workflow (Figure 1A) builds the basis
for pSIRM. The GC-MS analysis follows the protocol
introduced by Roessner-Tunali and co-workers [19] with
adaptations indicated in Kempa et al. [21]. We further re-
fined the chromatography in order to detect and quantify
CCM intermediates. We specifically identified conditions
for the reliable separation and quantification of pyruvate
and lactate (Figure 1B). Further improvements were
made using a thermo-regulated injector, resulting in the
temperature-dependent transfer of compounds from
the liner to the column, and by optimizing temperature
program and gas flow (see ‘Methods’ section).
Cell harvest strategy
The separation of mammalian cell cultures from nutrient-
rich culture medium without disturbing the cellular meta-
bolic homeostasis is crucial. Both cold and heat inactivation
(quenching) of metabolism, with or without washing steps,
have been reported previously [22-24].
To overcome these problems, we designed a cell-
harvesting strategy aimed at preserving the metabolic
homeostasis during harvest that involves (i) exchange
of culture medium prior to pSIRM experiment (2–4 h)
to minimize concentration changes of nutrients during
stable isotope pulse labeling and (ii) the continuous
supply of major nutrients during the whole harvest,
preventing the disruption of glycolysis or glutaminolysis
(Additional file 1: Figure S1).
Depending on the duration of incubation, 13C-substrates
are either added to a full label medium containing all
factors and nutrients or to a label buffer containing
main nutrients (e.g., glucose and glutamine), buffers,
and salts to maintain osmolality and pH. In both cases,
one major nutrient is replaced by carbon-13 variant
(Additional file 1: Table S1).
The use of label buffer for pSIRM experiments is ap-
propriate for incubation times not longer than 5 min.
Figure 1 pSIRM workflow including sample preparation, identification, and quantification of metabolites. (A) Scheme of the
experimental workflow from cell culture and cell harvest to GC-MS measurement. (B) A representative GC-MS selected ion chromatogram
obtained from a cell culture sample using temperature-controlled and split injection. Due to the method, the peaks of pyruvate and lactate are
baseline separated, detected, and quantified. The majority of phosphates are distinguishable by their retention behavior. (C) Distribution of the
coefficient of variation (CoV) of the measured metabolite quantities from five biological replicates; distinct compound classes are indicated. (D)
Spike-in experiment in order to test recovery of metabolites (see also Additional file 1: Table S5). Therefore, the samples were measured alone
and with spiked-in quantification mixtures at seven dilutions. (E) Absolute quantities of metabolites of T98G cells ranked by concentrations.
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gested. Adherent cell lines are labeled while growing
attached to their plates. Growth medium is replaced
with pre-warmed full label medium. After incubation,
the cells are rinsed with label buffer for a few seconds.
Immediate adding of pre-cold methanol (50% v/v, −20°C)
quenches all cellular processes directly and initiates me-
tabolite extraction (see ‘Methods’ section).
Reproducibility
In order to test the reproducibility of metabolite quantifica-
tion, T98G cells were harvested, pooled, and measured six
times independently, thereby giving the technical variance
of the method. Five independently grown plates were
treated separately during harvest and labeling, and mea-
sured in three technical replicates to evaluate the biological
reproducibility (Additional file 1: Figure S2). We observed
that 80% of metabolites showed a technical variation below
15% (Figure 1C and Additional file 1: Table S2).Quantification of CCM metabolites
Absolute quantification of metabolites improves meta-
bolomics analyses. It enables inter-batch and inter-
laboratory comparison and is a prerequisite for
quantitative modeling. Different methods for absolute
quantification have been described: isotopic dilution is
often applied for liquid chromatography-mass spectrom-
etry (LC-MS)-based quantification [25]. This strategy en-
ables correction for strong matrix effects as well as ion
suppression. However, the experimentally introduced
isotope-labeled substances may interfere with the
measurement of isotopomer distributions for metabolic
flux analyses, making it necessary to run different
measurements for quantification and isotopomer ex-
traction [26,27]. Electron impact ionization (EI) is the
standard ionization technique of GC-MS. This harsh
ionization allows monitoring even of uncharged mole-
cules, such as alkanes, and suffers less from ion sup-
pression. In order to quantify metabolites, we established
Figure 2 pSIRM workflow including the determination and calculation of stable isotope incorporation. (A) Data analysis workflow from
GC-MS raw data up to quantification and the calculation of 13C-label incorporation. (B) Map of the central carbon metabolism highlighting
detection and quantification of intermediates as well as evaluation of stable isotope enrichment after application of 13C-glucose or 13C-glutamine
in cell culture experiments. (C) Visualization of mass isotopomer fractions (MIF) of a mass fragment of 12C-glucose (left) and a 1:1 mixture of 12C- and
13C1-glucose (right). Targeted (Formula 1.1–1.3) and position-independent (Formula 2) calculation strategies provide the determination of
13C-label incorporation (L in (%)). (D) Calculation strategies were validated by the analysis of known ratios of 12C-glucose: 13C1-glucose.
Shown are expected versus measured stable isotope incorporation comparing both correction strategies.
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metabolites, mimicking the composition of the cellular
metabolome. This mixture is composed of 63 compounds
(Additional file 1: Table S3) and is measured in eight dif-
ferent dilutions spanning 3 orders of magnitude, resulting
in 73 calibration curves when considering multiple deri-
vates. Out of these curves, 54 delivered a regression
curve with R2 > 0.95. Recovery and quantification of
metabolites are influenced by several factors [28]. To
test the accuracy and concentration range suitable for
quantification, we performed a ‘spike-in’ experiment.
We thus measured the quantitative mixture and
biological extracts separately as well as the biological
extract with spiked-in quantitative mixture. The com-
parison of the derived concentration values demon-
strates the reliability of our approach. The majority of
the compounds showed similar curves which were
shifted by the quantity found in the added biological
samples (Figure 1D and Additional file 1: Figure S3,
Table S4). The recovery of the quantified compounds is,on average, 111% (Additional file 1: Table S5)—from a
typical cell culture, around 40 metabolites can be reliably
quantified in absolute terms (Figure 1E and Additional file 1:
Table S6).
Determination of time-resolved isotope incorporation rates
The concept of mass isotopomer analysis [29,30] relies
on the information about the incorporation of stable
isotopes in the metabolite pools, which is inherited in
the intensity shift within isotopomers. A prerequisite
for a reliable analysis of isotopomers is the extraction
of the corresponding mass spectra from GC-MS chro-
matograms. To determine the stable isotope incorpor-
ation in intermediates of CCM, we have established the
pSIRM data analysis workflow (Figure 2A). With this
approach, the quantity of a compound and the degree
of stable isotope incorporation can be determined from the
peak intensities and distribution of the mass isotopomers
within the same measurement (Figure 2B). We com-
piled a list of mass pairs for the calculation of stable
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partially overlapping with previously published data [28]
(Additional file 1: Table S7).
To analyze the quantitative isotopomer distribution
of the corresponding fragments, peak lists including the
mass spectral information were generated with the vendor
software ChromaTOF and exported as tab-separated .txt
files. The MetMax Software [21] provides the extraction
of intensities within pre-defined mass ranges from these
txt files for the determination of MIF.
Mathematical approaches to calculate stable isotope
enrichment [31] are already incorporated into existing
software packages [32]. Usually, these approaches require
the complete knowledge of the chemical composition
of the molecular fragment analyzed. Here, we established
a method to calculate stable isotope incorporation by
subtracting natural occurring stable isotope abundances
from experimentally derived mass spectra. This phenom-
enological approach does not require prior knowledge of
the chemical composition of the fragments. Furthermore,
this strategy takes into account concentration-dependent
changes of the mass isotopomer distributions, which are
laborious to calculate (Additional file 1: Figure S4). The
incorporation of carbon-13 induces an intensity shift
from the unlabeled position (m + 0) to the labeled position
(m + n) corresponding to the number of incorporated
carbon atoms. An example illustrating the incorporation
of one carbon-13 is shown in Figure 2C. The 13C incorp-
oration is defined as the ratio of the mass fraction at the
position m + n of carbon-13 incorporation (Sexp + n) to the
sum of the intensities at m + 0 and m + n (Snat + Sexp + n).
This simplified calculation leads to an overestimation
of label incorporation due to naturally occurring carbon,
nitrogen, and silicone isotopes in the compound and de-
rivatization groups. The measurement of non-labeled
reference spectra enables correcting for natural isotope
abundance Snat + n (Formula 1.3) and therefore to deter-
mine the actual 13C incorporation Sinc + n (Formula 1.2).
Instead of the measurement-derived Sexp + n, the use
of the corrected Sinc + n provides a reliable estimate
of 13C-carbon incorporation (Formula 1.1) in a position-
dependent manner. The targeted strategy assumes a 13C
incorporation at a single position, which holds true for most
glycolytic intermediates after application of 13C6-glucose
(Additional file 1: Table S7).
Incorporation of 13C-carbon atoms at multiple posi-
tions was addressed with an untargeted strategy. To
calculate isotope incorporation into TCA cycle inter-
mediates, we additionally employed a strategy to calcu-
late the total label incorporation from the remaining
intensity of the light fragment (Snat) compared to the
overall intensity of the isotopomer (Formula 2). Therefore,
the comparison of intensities of the 12C-fragments of the
reference isotopomer (Rnat) and sample isotopomer (Snat)enables the determination of label incorporation in a
position-independent manner.
We verified the calculation strategies by mixing known
amounts of 13C1-glucose with
12C-glucose and comparing
the measured with the calculated isotope incorporation.
The uncorrected strategy leads to an over-estimation
of the label incorporation, as expected. The targeted and
position-independent strategies reflected precisely the cor-
rect amount of 13C-label (Figure 2D and Additional file 1:
Tables S8 and S9). Finally, we determined the label in-
corporation in T98G cells with technical and biological
variation below 4% for the majority of metabolic inter-
mediates (Additional file 1: Table S10).
Application of pSIRM
Feeding cells with 13C-glucose allows monitoring of the
activity of CCM, specifically of glycolysis and its branching
points (Figure 3A) at the level of (1) G6P into the pentose
phosphate pathway (PPP) and glycogen synthesis, (2)
DHAP/GAP into PPP and (3) into Glyc3P (lipid synthesis),
(4) 3PGA into serine and glycine metabolism, and (5)
pyruvate into lactate, alanine or acetyl-CoA. The absolute
concentration of 13C isotope-labeled intermediates was
calculated for T98G cells (Additional file 1: Figure S5). Fur-
ther, we compared four different cell lines (HeLa, HEK293,
T98G, and HCT-116) cultivated under identical nutrient
conditions fed with u-13C-glucose for 3 min. The labeled
fractions of metabolites (the product of peak intensity
multiplied with percentage of label incorporation) were
compared relative to T98G cells (Figure 3B and Additional
file 1: Table S11). Using this approach, clear differences
among the tested cell lines were observed. HeLa cells
showed the highest glycolytic activity. 13C isotope in-
corporation of fructose was detected in the HeLa and
HEK293 cells, while 13C-labeled fructose-1-phosphate was
detected only in the HeLa cells. The time-dependent label
incorporation in ribose-5-phosphate, an important inter-
mediate of the pentose phosphate pathway, was compar-
able among all cell lines—nearly identical for G6P, DHAP,
Pyr, Lac, and Cit; only the T98G cells displayed a different
labeling pattern. The HEK293 cells showed higher ac-
tivity in amino acid synthesis as the labeled fractions of
alanine and serine were increased. These results clearly
demonstrate the ability of the presented method in
order to highlight variations in carbon routing within
different cellular systems.
We also analyzed the mode of action of two glycolytic
inhibitors, 2DG and BrPyr. The T98G cells were treated
for 12 min with each inhibitor (2 mM), followed by 3 min
of 13C-glucose incorporation in the presence of each inhibi-
tor (Figure 3C). The BrPyr treatment reduced the labeled
fraction of G6P and F6P, whereas the total concentration of
these compounds increased (Additional file 1: Table S7
and Table S12). The concentration of 3PGA diminished
Figure 3 Application of pSIRM for tracking carbon routing and monitoring influence of inhibitor treatment in cell cultures. (A) Scheme
of the central carbon metabolism (CCM) and branching points of glycolysis (1 to 5). Summarized are the results of the analyses of carbon routing in
different cell lines and the impact of BrPyr or 2DG (T98G only) on CCM. (B) Quantification of 13C6-glucose incorporation within metabolic intermediates
(labeled quantities) of T98G, HEK293, HeLa, and HCT-116 cells. Arrows between metabolites indicate links within the biochemical network. The data are
presented relative to the T98G cells. (C) Visualization of the results of the pSIRM analysis of BrPyr- and 2DG-treated T98G cells.
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glycolysis was nearly completely inhibited (Figure 3C).
The carbon flow into pyruvate, lactate, and citrate was
reduced by around 100%, verifying specific suppression
of GAPDH activity. The alterations within the glycolysis
upstream may be explained by feedback inhibition of hexo-
kinase by the accumulation of hexose phosphates. Further,
lower concentrations of BrPyr reduced the carbon flow
though glycolysis (Additional file 1: Figure S8). In compari-
son, 2 mM 2DG reduced the amount of the 13C fraction
of hexose phosphates by 20%–30% and affected only mar-
ginally the isotope incorporation into pyruvate and lactate
(Additional file 1: Table S13). Interestingly, 13C-glucose
incorporation into citrate increased after 2DG treatment
(Figure 3C). Increasing the 2DG concentration to 10 mM, a
stronger inhibition was observed—mainly due to an overall
decline of metabolite pool sizes rather than a decrease
of 13C-label incorporation (Additional file 1: Figure S7).
Discussion
Isotope pulse labeling is the ultimate tool to unravel
metabolic pathways in plant and animal cells. The furtherdevelopment of analytical techniques such as mass spec-
trometry and nuclear magnetic resonance allows quanti-
tative and structurally resolved analysis of stable isotope
incorporation, thereby enabling a time-resolved analysis of
known metabolic pathways and, potentially, the discovery
of new connections within the metabolic network [33-35].
Here, we report that the pSIRM workflow integrates in-
formation about stable isotope incorporation and metabo-
lomics analyses by introducing additional time-dependent
information of the underlying pathway activities from
a single measurement in a quantitative manner.
We have improved the cell-handling protocol, allowing
for removal of abundant compounds from cultivation
medium, and optimized sample preparation and GC-MS
measurements. The combination of these improvements
has created a reproducible analytical platform with a high
coverage of CCM intermediates. Using GC-TOF-MS
technology offers further advantages: the quantification
of compounds suffers less from matrix effects due to the
strong EI, thus enabling the application of external calibra-
tion for absolute quantification of 38 metabolites simultan-
eously in the T98G cells. Using external calibration instead
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where the generation of sample material is limited, e.g.,
with primary cell lines or in vivo applications. The
propagation of errors is minimized when quantities
and isotope incorporation are measured from the same
sample. Further, the untargeted character of TOF-MS
allowed for the measurement of carbon-13 incorporation
in an unbiased manner [36].
The pSIRM approach follows the concept of Nöh and
Wiechert who proposed a distinct advantage of dynamic
labeling in comparison to steady-state label incorpor-
ation [37]. Uniformly labeled 13C-substrates that do not
yield information in stationary labeling can be used for
dynamic labeling (Additional file 1: Figure S6), making
analysis both less expensive and more generally applicable.
Using pSIRM, we aimed to compare different metabolic
states rather than perfect numerical description of the
underlying fluxes. The functionality of this concept was
demonstrated by decoding the metabolic basis of synthetic
lethality induced by metabolic inhibition of senescent
lymphoma cells [38] and in MYC-driven cancer cells
after ARK5 inhibition [18].
Finally, dynamic labeling allowed the measurement
of short-term changes within metabolism that could
not be monitored by long-term label incorporation ex-
periments. The application of pSIRM in combination
with metabolic inhibitors or toxins may resolve the
position of a drug target within the metabolic network.
This is illustrated by the inhibition of glycolysis by BrPyr
and by the failure of 2DG to acutely block glycolysis. In
agreement with previous studies [39,40], we observed an
increased concentration of hexose phosphates after BrPyr
treatment (Additional file 1: Table S12), indicating that
hexokinase is not the major target of this inhibitor. A
strong decline of carbon flow downstream of GAPDH
identifies this enzyme as target of BrPyr in agreement
with literature data [41,42].
In comparison, 2DG did not block glycolysis directly
under the conditions used. A 2 mM 2DG reduced
the 13C-labeled fraction of hexose phosphates by only
20%–30% and did not affect the pyruvate or lactate levels.
At the same time, a concentration- and time-dependent
increase of 2-deoxyglucose-phosphate (2DG-P), resulting
from phosphorylation by hexokinase, was detectable
(Additional file 1: Figure S7).
2DG-P was found to accumulate inside the cells to
high levels and exceeding the G6P concentrations by
10- to 20-fold (Additional file 1: Figure S4). As a response,
cells adapted to 2DG treatment by increasing the car-
bon flow into citrate (Figure 3C), as reported previ-
ously [43,44]. From these results, we conclude that an
accumulation of 2DG-P depletes the cellular phos-
phate pool by scavenging phosphate, thereby impairing
ADP re-phosphorylation. Thus, ATP-dependent processesin the cell, such as glycolysis, may be slowed down. In-
deed, Hoffmann and co-workers measured concentra-
tions of ATP and G6P in HepG2 cells and found a ratio
of 1:20 (G6P/ATP) [24]. Thus, the levels of 2DG-P in
our experiments may be at the same levels as of ATP.
Very high concentrations of 2DG (10 mM) reduced iso-
tope incorporation in pyruvate up to 80%, while isotope
incorporation rates in G6P were unaltered. Moreover, it
has been shown that 2DG treatment interferes with gly-
cosylation of proteins, inducing stress in the endoplas-
mic reticulum [45,46].
In summary, the analysis of metabolic reprogram-
ming after application of metabolic inhibitors in acute
time scales has the potential to improve metabolic re-
search. The dissection of primary metabolic effects
from secondary consequences is now possible. This
will enable the evaluation of the direct impact of
small molecules on metabolic pathways from meta-
bolic changes provoked by transcriptional reprogram-
ming. Thus, pSIRM has the potential to support
quantitative and time-resolved understanding of metabolic
regulation.
Conclusions
In the present work, we describe a GC-MS-based strat-
egy to analyze and quantify stable isotope incorporation
into intermediates of central carbon metabolism. We
have used pSIRM to analyze the acute effects induced
by the addition of 2DG and BrPyr. By analyzing the ac-
tion of these compounds on the glycolytic pathway of a
cancer cell line, we observed that 2DG acts indirectly,
perhaps due to the depletion of the intracellular phos-
phate pool. Methods designed for the quantification of
stable isotope incorporation at an isotopic instationary
state, such as pSIRM, will become very useful when ana-
lyzing the isotope incorporation in vivo. Ensuring an
isotopic steady state for in vivo metabolic analysis is very
time consuming and expensive. Although LC-MS-based
methods for metabolomics analyses and quantification
of isotope incorporation are widely used, GC-MS-based
methods offer some advantages. The electron impact
ionization is very harsh and allows a highly sensitive de-
tection of less-charged molecules and a reliable quanti-
fication. Due to the sample preparation and the superior
separation capacity of gas chromatography, compounds
spanning a wide range of polarity can be separated. Spe-
cifically, the separation of stereoisomers of carbohy-
drates or organic acids, which are hardly distinguishable
by LC-MS-based methods, can be achieved by GC-MS.
The pSIRM workflow also has the advantage of allowing
the assessment of 13C enrichment and metabolite abun-
dance in the same sample. This simplifies the workflow
for cell culture experiments and is prerequisite when
analyzing metabolic dynamics in vivo.
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